A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. Our approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Our most advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (“SM”), a serious and rare disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (“GIST”), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib is a highly selective and potent KIT inhibitor with the potential to provide a new treatment option for these patient populations.
| Metric | TTM | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | 0 | - | 22M | - | - |
| Net Income | -329M | -179M | -32M | -35M | -26M |
| EPS | $-2.16 | $-16.17 | $-4.18 | $-5.56 | $-10.04 |
| Free Cash Flow | -266M | -36M | -42M | -33M | -27M |
| ROIC | -28.1% | -76.4% | -80.0% | -57.4% | -53.2% |
| Gross Margin | - | - | - | - | - |
| Debt/Equity | 0.35 | 0.07 | 0.56 | 0.43 | -0.43 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -333M | -82M | -32M | -36M | -26M |
| Operating Margin | 0.0% | - | -143.0% | - | - |
| ROE | -51.7% | -76.4% | -100.2% | -57.4% | - |
| Shares Outstanding | 162M | 46M | 37M | 6M | 8M |
| Metric | 2017 | 2018 | |||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | N/A | N/A | 22M | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| R&D | 30M | 38M | 44M | 26M | 270M |
| SG&A | 4.7M | 7.5M | 11M | 17M | 64M |
| EBIT | -26M | -36M | -32M | -82M | -333M |
| Op. Margin | N/A | N/A | -143.0% | N/A | 0.0% |
| Net Income | -26M | -35M | -32M | -179M | -329M |
| Net Margin | N/A | N/A | -141.5% | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 78K | 7.5M | 0 |
| Returns on Capital | |||||
| ROIC | -53.2% | -57.4% | -80.0% | -76.4% | -28.1% |
| ROE | N/A | -57.4% | -100.2% | -76.4% | -51.7% |
| ROA | -52.0% | -40.2% | -64.4% | -71.4% | -35.1% |
| Cash Flow | |||||
| Op. Cash Flow | -26M | -32M | -42M | -36M | -264M |
| Free Cash Flow | -27M | -33M | -42M | -36M | -266M |
| Owner Earnings | -28M | -37M | -46M | -43M | -313M |
| CapEx | 912K | 549K | 33K | 0 | 1.6M |
| Maint. CapEx | 1.2M | 1.3M | 1.3M | 720K | 2.6M |
| Growth CapEx | 0 | 0 | 0 | N/A | 0 |
| D&A | 1.2M | 1.3M | 1.3M | 720K | 2.6M |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.3M | 3.1M | 3.2M | 6.0M | 46M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | N/A | N/A | N/A | N/A | -678M |
| Cash & Equiv. | 28M | 56M | 37M | 242M | 901M |
| Long-Term Debt | N/A | N/A | N/A | N/A | 223M |
| Debt/Equity | -0.43 | 0.43 | 0.56 | 0.07 | 0.35 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A |
| Equity | -49M | 60M | 32M | 235M | 636M |
| Total Assets | 49M | 86M | 49M | 251M | 938M |
| Total Liabilities | 21M | 26M | 18M | 16M | 301M |
| Intangibles | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -51M | -92M | -124M | -199M | -1.2B |
| Working Capital | 31M | 56M | 27M | 232M | 846M |
| Current Assets | 42M | 81M | 41M | 245M | 910M |
| Current Liabilities | 11M | 25M | 13M | 13M | 64M |
| Per Share Data | |||||
| EPS | -10.04 | -5.56 | -4.18 | -16.17 | -2.16 |
| Owner EPS | -3.77 | -5.94 | -1.24 | -0.93 | -1.93 |
| Book Value | -6.49 | 9.69 | 0.85 | 5.12 | 3.92 |
| Cash Flow/Share | -3.43 | -5.23 | -1.12 | -0.78 | -2.01 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 7.5M | 6.2M | 37.2M | 45.8M | 162.3M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | N/A | N/A | -16.9 |
| P/FCF | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 1.9 | 3.5 | 2.4 | 9.3 |
| Price/Sales | N/A | N/A | 17.7 | N/A | N/A |
| FCF Yield | N/A | -29.4% | -37.7% | -6.3% | -4.5% |
| Market Cap | N/A | 112M | 110M | 565M | 5.9B |
| Avg. Price | N/A | 44.83 | 10.68 | 6.47 | 36.52 |
| Year-End Price | N/A | 18.08 | 2.96 | 12.34 | 36.52 |
Cogent Biosciences, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Cogent Biosciences, Inc. (COGT) has a 5-year average return on invested capital (ROIC) of -66.8%. This is below average and may indicate limited pricing power.
Cogent Biosciences, Inc. (COGT) has a market capitalization of $5.9B. It is classified as a mid-cap stock.
Cogent Biosciences, Inc. (COGT) does not currently pay a regular dividend.
Cogent Biosciences, Inc. (COGT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Cogent Biosciences, Inc. (COGT) generated $-36 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Cogent Biosciences, Inc. (COGT) has a debt-to-equity ratio of 0.07. This indicates a conservatively financed balance sheet.
Cogent Biosciences, Inc. (COGT) reported earnings per share (EPS) of $-16.17 in its most recent fiscal year.
Cogent Biosciences, Inc. (COGT) has a return on equity (ROE) of -76.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 4 years of financial data for Cogent Biosciences, Inc. (COGT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Cogent Biosciences, Inc. (COGT) has a book value per share of $5.12, based on its most recent annual SEC filing.